Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS

Nature

Volumn 523, Issue 7559, 2015, Pages 183-188

  Krönke, Jan ^a,b,c   Fink, Emma C ^a,c   Hollenbach, Paul W ^d   MacBeth, Kyle J ^d   Hurst, Slater N ^a   Udeshi, Namrata D ^c   Chamberlain, Philip P ^d   Mani, D R ^c   Man, Hon Wah ^d   Gandhi, Anita K ^d   Svinkina, Tanya ^c   Schneider, Rebekka K ^a   McConkey, Marie ^a   Järås, Marcus ^a   Griffiths, Elizabeth ^e   Wetzler, Meir ^e   Bullinger, Lars ^b   Cathers, Brian E ^d   Carr, Steven A ^c   Chopra, Rajesh ^d   Ebert, Benjamin L ^a,c   more..

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d CELGENE CORPORATION   (United States)

^e ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE IALPHA; CASEIN KINASE IALPHA 1; LENALIDOMIDE; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; CASEIN KINASE I; IMMUNOLOGIC FACTOR; PEPTIDE HYDROLASE; THALIDOMIDE; UBIQUITIN PROTEIN LIGASE;

AMINO ACID; BLOOD SYSTEM DISORDER; CELLS AND CELL COMPONENTS; CHROMOSOME; DEGRADATION; DRUG; DRUG RESISTANCE; ENZYME ACTIVITY; GENE EXPRESSION; HOMINID; PROTEIN; RODENT; SUBSTRATE;

5Q- SYNDROME; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME DEGRADATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FEMALE; HAPLOINSUFFICIENCY; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPECIES DIFFERENCE; UBIQUITINATION; AMINO ACID SEQUENCE; ANALOGS AND DERIVATIVES; ANIMAL; CELL LINE; CHEMISTRY; DRUG EFFECTS; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; JURKAT CELL LINE; K562 CELL LINE; METABOLISM; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; PATHOPHYSIOLOGY; PROTEIN DEGRADATION; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; ANIMALS; CASEIN KINASE I; CELL LINE; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; IMMUNOLOGIC FACTORS; JURKAT CELLS; K562 CELLS; MICE; MOLECULAR SEQUENCE DATA; MYELODYSPLASTIC SYNDROMES; PEPTIDE HYDROLASES; PROTEOLYSIS; SEQUENCE ALIGNMENT; SEQUENCE DELETION; SPECIES SPECIFICITY; THALIDOMIDE; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84936930551     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14610     Document Type: Article

References (38)

1. Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345-1350 (2010).
2. Krönke, J. et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 343, 301-305 (2014).
3. Lu, G. et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343, 305-309 (2014).
4. Gandhi, A. K. et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos viamodulation of the E3 ubiquitin ligase complex CRL4CRBN. Br. J. Haematol. 164, 811-821 (2014).
5. List, A. et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N. Engl. J. Med. 355, 1456-1465 (2006).
6. List, A. et al. Efficacy of lenalidomide inmyelodysplastic syndromes. N. Engl. J.Med. 352, 549-557 (2005).
7. Fenaux, P. et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 118, 3765-3776 (2011).
8. Pellagatti, A. et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC genemapping to the commonly deleted region in 5q-syndrome patients. Proc. Natl Acad. Sci. USA 104, 11406-11411 (2007).
9. Wei, S. et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc. Natl Acad. Sci. USA 106, 12974-12979 (2009).
10. Boultwood, J. et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 99, 4638-4641 (2002).
11. Graubert, T. A. et al. Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS ONE 4, e4583 (2008).
12. Ong, S. E. et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386 (2002).
13. Udeshi, N. D., Mertins, P., Svinkina, T. & Carr, S. A. Large-scale identification of ubiquitination sites by mass spectrometry. Nature Protocols 8, 1950-1960 (2013).
14. Boultwood, J. et al. Gene expression profiling of CD341 cells in patients with the 5q2 syndrome. Br. J. Haematol. 139, 578-589 (2007).
15. Schneider, R.K. et al. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell 26, 509-520 (2014).
16. Järas, M. et al. Csnk1a1inhibition hasp53-dependent therapeutic efficacy in acute myeloid leukemia. J. Exp. Med. 211, 605-612 (2014).
17. Huart, A. S., MacLaine, N. J., Meek, D. W. & Hupp, T. R. CK1a plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability. J. Biol. Chem. 284, 32384-32394 (2009).
18. Wu, S., Chen, L., Becker, A., Schonbrunn, E. & Chen, J. Casein kinase 1a regulates an MDMX intramolecular interaction to stimulate p53 binding. Mol. Cell. Biol. 32, 4821-4832 (2012).
19. Elyada, E. et al. CKIa ablation highlights a critical role for p53 in invasiveness control. Nature 470, 409-413 (2011).
20. Knippschild, U. et al. The CK1 family: contribution to cellular stress response and its role in carcinogenesis. Front. Oncol. 4, 96 (2014).
21. Venerando, A., Ruzzene, M. & Pinna, L. A. Casein kinase: the triple meaning of a misnomer. Biochem. J. 460, 141-156 (2014).
22. Fratta, I. D., Sigg, E. B. &Maiorana, K. Teratogenic effects of thalidomide in rabbits, rats, hamsters, and mice. Toxicol. Appl. Pharmacol. 7, 268-286 (1965).
23. Chesi,M. et al. Drug response in a genetically engineeredmousemodel ofmultiple myeloma is predictive of clinical efficacy. Blood 120, 376-385 (2012).
24. Fischer, E.S. et al. Structure of theDDB1-CRBNE3ubiquitinligase incomplex with thalidomide. Nature 512, 49-53 (2014).
25. Chamberlain, P. P. et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nature Struct. Mol. Biol 21, 803-809 (2014).
26. Jädersten, M. et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J. Clin. Oncol. 29, 1971-1979 (2011).
27. Rauniyar, N. & Yates, J. R. III. Isobaric labeling-based relative quantification in shotgun proteomics. J. Proteome Res. 13, 5293-5309 (2014).
28. Frei, E. III. Gene deletion: a new target for cancer chemotherapy. Lancet 342, 662-664 (1993).
29. Nijhawan, D. et al. Cancer vulnerabilities unveiled by genomic loss. Cell 150, 842-854 (2012).
30. Ebert, B. L. et al. Identification of RPS14 as a 5q-syndrome gene by RNA interference screen. Nature 451, 335-339 (2008).
31. Narla, A. & Ebert, B. L. Ribosomopathies: human disorders of ribosome dysfunction. Blood 115, 3196-3205 (2010).
32. Yang, Y. et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 21, 723-737 (2012).
33. Mertins, P. et al. Integrated proteomic analysis of post-translationalmodifications by serial enrichment. Nature Methods 10, 634-637 (2013).
34. Bland, J.M. & Altman, D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1, 307-310 (1986).
35. Smyth,G. K. Linearmodels andempirical bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and molecular biology 3, Article 3 (2004).
36. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc., B (1995).
37. Heckl, D. et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. Nature Biotechnol. (2014).
38. Weekes, M. P. et al. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157, 1460-1472 (2014).